Frequency	O
of	O
BCR	B:C1835417
-	I:C1835417
ABL	I:C1835417
Transcript	O
Types	O
in	O
Syrian	O
CML	O
Patients	O
.	O

Frequency	O
of	O
BCR	O
-	I:C1835417
ABL	I:C1835417
Transcript	B:C1519595
Types	O
in	O
Syrian	O
CML	O
Patients	O
.	O

Frequency	O
of	O
BCR	O
-	I:C1835417
ABL	I:C1835417
Transcript	O
Types	O
in	O
Syrian	B:C0337819
CML	O
Patients	O
.	O

Frequency	O
of	O
BCR	O
-	I:C1835417
ABL	I:C1835417
Transcript	O
Types	O
in	O
Syrian	O
CML	B:C0023473
Patients	O
.	O

In	O
Syria	B:C0039138
,	O
CML	O
patients	O
are	O
started	O
on	O
tyrosine	O
kinase	I:C2757011
inhibitors	I:C2757011
(	O
tyrosine	O
kinase	I:C2757011
inhibitors	I:C2757011
)	O
and	O
monitored	O
until	O
complete	O
molecular	O
response	I:C4054479
is	O
achieved	O
.	O

In	O
Syria	O
,	O
CML	B:C0023473
patients	O
are	O
started	O
on	O
tyrosine	O
kinase	I:C2757011
inhibitors	I:C2757011
(	O
tyrosine	O
kinase	I:C2757011
inhibitors	I:C2757011
)	O
and	O
monitored	O
until	O
complete	O
molecular	O
response	I:C4054479
is	O
achieved	O
.	O

In	O
Syria	O
,	O
CML	O
patients	O
are	O
started	O
on	O
tyrosine	B:C2757011
kinase	I:C2757011
inhibitors	I:C2757011
(	O
tyrosine	O
kinase	I:C2757011
inhibitors	I:C2757011
)	O
and	O
monitored	O
until	O
complete	O
molecular	O
response	I:C4054479
is	O
achieved	O
.	O

In	O
Syria	O
,	O
CML	O
patients	O
are	O
started	O
on	O
tyrosine	O
kinase	I:C2757011
inhibitors	I:C2757011
(	O
tyrosine	B:C2757011
kinase	I:C2757011
inhibitors	I:C2757011
)	O
and	O
monitored	O
until	O
complete	O
molecular	O
response	I:C4054479
is	O
achieved	O
.	O

In	O
Syria	O
,	O
CML	O
patients	O
are	O
started	O
on	O
tyrosine	O
kinase	I:C2757011
inhibitors	I:C2757011
(	O
tyrosine	O
kinase	I:C2757011
inhibitors	I:C2757011
)	O
and	O
monitored	O
until	O
complete	O
molecular	B:C4054479
response	I:C4054479
is	O
achieved	O
.	O

BCR	B:C1835417
-	I:C1835417
ABL	I:C1835417
mRNA	O
transcript	O
type	O
is	O
not	O
routinely	O
identified	O
,	O
contrary	O
to	O
the	O
recommendations	O
.	O

BCR	O
-	I:C1835417
ABL	I:C1835417
mRNA	B:C0035696
transcript	O
type	O
is	O
not	O
routinely	O
identified	O
,	O
contrary	O
to	O
the	O
recommendations	O
.	O

BCR	O
-	I:C1835417
ABL	I:C1835417
mRNA	O
transcript	B:C1519595
type	O
is	O
not	O
routinely	O
identified	O
,	O
contrary	O
to	O
the	O
recommendations	O
.	O

In	O
this	O
study	O
we	O
aimed	O
to	O
identify	O
the	O
frequency	O
of	O
different	O
BCR	B:C1835417
-	I:C1835417
ABL	I:C1835417
transcripts	O
in	O
Syrian	O
CML	O
patients	O
and	O
highlight	O
their	O
significance	O
on	O
monitoring	O
and	O
treatment	O
protocols	I:C0040808
.	O

In	O
this	O
study	O
we	O
aimed	O
to	O
identify	O
the	O
frequency	O
of	O
different	O
BCR	O
-	I:C1835417
ABL	I:C1835417
transcripts	B:C1519595
in	O
Syrian	O
CML	O
patients	O
and	O
highlight	O
their	O
significance	O
on	O
monitoring	O
and	O
treatment	O
protocols	I:C0040808
.	O

In	O
this	O
study	O
we	O
aimed	O
to	O
identify	O
the	O
frequency	O
of	O
different	O
BCR	O
-	I:C1835417
ABL	I:C1835417
transcripts	O
in	O
Syrian	B:C0337819
CML	O
patients	O
and	O
highlight	O
their	O
significance	O
on	O
monitoring	O
and	O
treatment	O
protocols	I:C0040808
.	O

In	O
this	O
study	O
we	O
aimed	O
to	O
identify	O
the	O
frequency	O
of	O
different	O
BCR	O
-	I:C1835417
ABL	I:C1835417
transcripts	O
in	O
Syrian	O
CML	B:C0023473
patients	O
and	O
highlight	O
their	O
significance	O
on	O
monitoring	O
and	O
treatment	O
protocols	I:C0040808
.	O

In	O
this	O
study	O
we	O
aimed	O
to	O
identify	O
the	O
frequency	O
of	O
different	O
BCR	O
-	I:C1835417
ABL	I:C1835417
transcripts	O
in	O
Syrian	O
CML	O
patients	O
and	O
highlight	O
their	O
significance	O
on	O
monitoring	O
and	O
treatment	B:C0040808
protocols	I:C0040808
.	O

CML	B:C0023473
patients	O
positive	O
for	O
BCR	O
-	I:C1835417
ABL	I:C1835417
transcripts	O
by	O
quantitative	O
RT	O
-	I:C0599161
PCR	I:C0599161
were	O
enrolled	O
.	O

CML	O
patients	O
positive	B:C1446409
for	O
BCR	O
-	I:C1835417
ABL	I:C1835417
transcripts	O
by	O
quantitative	O
RT	O
-	I:C0599161
PCR	I:C0599161
were	O
enrolled	O
.	O

CML	O
patients	O
positive	O
for	O
BCR	B:C1835417
-	I:C1835417
ABL	I:C1835417
transcripts	O
by	O
quantitative	O
RT	O
-	I:C0599161
PCR	I:C0599161
were	O
enrolled	O
.	O

CML	O
patients	O
positive	O
for	O
BCR	O
-	I:C1835417
ABL	I:C1835417
transcripts	B:C1519595
by	O
quantitative	O
RT	O
-	I:C0599161
PCR	I:C0599161
were	O
enrolled	O
.	O

CML	O
patients	O
positive	O
for	O
BCR	O
-	I:C1835417
ABL	I:C1835417
transcripts	O
by	O
quantitative	O
RT	B:C0599161
-	I:C0599161
PCR	I:C0599161
were	O
enrolled	O
.	O

BCR	B:C1835417
-	I:C1835417
ABL	I:C1835417
transcript	O
types	O
were	O
investigated	O
using	O
a	O
home	O
-	O
made	O
PCR	O
method	O
that	O
was	O
adapted	O
from	O
published	O
protocols	I:C0936005
and	O
optimized	O
.	O

BCR	O
-	I:C1835417
ABL	I:C1835417
transcript	B:C1519595
types	O
were	O
investigated	O
using	O
a	O
home	O
-	O
made	O
PCR	O
method	O
that	O
was	O
adapted	O
from	O
published	O
protocols	I:C0936005
and	O
optimized	O
.	O

BCR	O
-	I:C1835417
ABL	I:C1835417
transcript	O
types	O
were	O
investigated	O
using	O
a	O
home	O
-	O
made	O
PCR	B:C0032520
method	O
that	O
was	O
adapted	O
from	O
published	O
protocols	I:C0936005
and	O
optimized	O
.	O

BCR	O
-	I:C1835417
ABL	I:C1835417
transcript	O
types	O
were	O
investigated	O
using	O
a	O
home	O
-	O
made	O
PCR	O
method	O
that	O
was	O
adapted	O
from	O
published	B:C0936005
protocols	I:C0936005
and	O
optimized	O
.	O

The	O
transcript	B:C1519595
types	O
were	O
then	O
confirmed	O
using	O
a	O
commercially	O
available	O
research	O
kit	I:C0812225
.	O

The	O
transcript	O
types	O
were	O
then	O
confirmed	O
using	O
a	O
commercially	O
available	O
research	B:C0812225
kit	I:C0812225
.	O

Twenty	O
-	O
four	O
transcripts	B:C1519595
were	O
found	O
in	O
21	O
patients	O
.	O

The	O
most	O
common	O
was	O
b2	O
a2	O
,	O
followed	O
by	O
b3a2	O
,	O
b3a3	B:C1519595
,	O
and	O
e1a3	O
present	O
solely	O
in	O
12	O
(	O
57.1	O
%	O
)	O
,	O
3	O
(	O
14.3	O
%	O
)	O
,	O
2	O
(	O
9.5	O
%	O
)	O
,	O
and	O
1	O
(	O
4.8	O
%	O
)	O
,	O
respectively	O
.	O

The	O
most	O
common	O
was	O
b2	O
a2	O
,	O
followed	O
by	O
b3a2	O
,	O
b3a3	O
,	O
and	O
e1a3	B:C1519595
present	O
solely	O
in	O
12	O
(	O
57.1	O
%	O
)	O
,	O
3	O
(	O
14.3	O
%	O
)	O
,	O
2	O
(	O
9.5	O
%	O
)	O
,	O
and	O
1	O
(	O
4.8	O
%	O
)	O
,	O
respectively	O
.	O

Three	O
samples	O
(	O
14.3	O
%	O
)	O
contained	O
dual	O
transcripts	B:C1519595
.	O

While	O
b3	O
a2	O
transcript	O
was	O
apparently	O
associated	O
with	O
warning	O
molecular	B:C4054479
response	I:C4054479
to	O
imatinib	O
treatment	O
,	O
b2	O
a2	O
,	O
b3a3	O
,	O
and	O
e1a3	O
transcripts	I:C1519595
collectively	O
proved	O
otherwise	O
(	O
P	O
=	O
0.047	O
)	O
.	O

While	O
b3	O
a2	O
transcript	O
was	O
apparently	O
associated	O
with	O
warning	O
molecular	O
response	I:C4054479
to	O
imatinib	B:C0935989
treatment	O
,	O
b2	O
a2	O
,	O
b3a3	O
,	O
and	O
e1a3	O
transcripts	I:C1519595
collectively	O
proved	O
otherwise	O
(	O
P	O
=	O
0.047	O
)	O
.	O

While	O
b3	O
a2	O
transcript	O
was	O
apparently	O
associated	O
with	O
warning	O
molecular	O
response	I:C4054479
to	O
imatinib	O
treatment	B:C0087111
,	O
b2	O
a2	O
,	O
b3a3	O
,	O
and	O
e1a3	O
transcripts	I:C1519595
collectively	O
proved	O
otherwise	O
(	O
P	O
=	O
0.047	O
)	O
.	O

While	O
b3	O
a2	O
transcript	O
was	O
apparently	O
associated	O
with	O
warning	O
molecular	O
response	I:C4054479
to	O
imatinib	O
treatment	O
,	O
b2	O
a2	O
,	O
b3a3	B:C1519595
,	O
and	O
e1a3	O
transcripts	I:C1519595
collectively	O
proved	O
otherwise	O
(	O
P	O
=	O
0.047	O
)	O
.	O

While	O
b3	O
a2	O
transcript	O
was	O
apparently	O
associated	O
with	O
warning	O
molecular	O
response	I:C4054479
to	O
imatinib	O
treatment	O
,	O
b2	O
a2	O
,	O
b3a3	O
,	O
and	O
e1a3	B:C1519595
transcripts	I:C1519595
collectively	O
proved	O
otherwise	O
(	O
P	O
=	O
0.047	O
)	O
.	O

It	O
might	O
be	O
advisable	O
to	O
identify	O
the	O
BCR	B:C1835417
-	I:C1835417
ABL	I:C1835417
transcript	O
type	O
in	O
CML	O
patients	O
at	O
diagnosis	O
,	O
using	O
an	O
empirically	O
verified	O
method	O
,	O
in	O
order	O
to	O
link	O
the	O
detected	O
transcript	O
with	O
the	O
clinical	O
findings	I:C0455712
,	O
possible	O
resistance	O
to	O
treatment	O
,	O
and	O
appropriate	O
monitoring	O
methods	I:C1283169
.	O

It	O
might	O
be	O
advisable	O
to	O
identify	O
the	O
BCR	O
-	I:C1835417
ABL	I:C1835417
transcript	B:C1519595
type	O
in	O
CML	O
patients	O
at	O
diagnosis	O
,	O
using	O
an	O
empirically	O
verified	O
method	O
,	O
in	O
order	O
to	O
link	O
the	O
detected	O
transcript	O
with	O
the	O
clinical	O
findings	I:C0455712
,	O
possible	O
resistance	O
to	O
treatment	O
,	O
and	O
appropriate	O
monitoring	O
methods	I:C1283169
.	O

It	O
might	O
be	O
advisable	O
to	O
identify	O
the	O
BCR	O
-	I:C1835417
ABL	I:C1835417
transcript	O
type	O
in	O
CML	B:C0023473
patients	O
at	O
diagnosis	O
,	O
using	O
an	O
empirically	O
verified	O
method	O
,	O
in	O
order	O
to	O
link	O
the	O
detected	O
transcript	O
with	O
the	O
clinical	O
findings	I:C0455712
,	O
possible	O
resistance	O
to	O
treatment	O
,	O
and	O
appropriate	O
monitoring	O
methods	I:C1283169
.	O

It	O
might	O
be	O
advisable	O
to	O
identify	O
the	O
BCR	O
-	I:C1835417
ABL	I:C1835417
transcript	O
type	O
in	O
CML	O
patients	O
at	O
diagnosis	O
,	O
using	O
an	O
empirically	O
verified	O
method	O
,	O
in	O
order	O
to	O
link	O
the	O
detected	O
transcript	B:C1519595
with	O
the	O
clinical	O
findings	I:C0455712
,	O
possible	O
resistance	O
to	O
treatment	O
,	O
and	O
appropriate	O
monitoring	O
methods	I:C1283169
.	O

It	O
might	O
be	O
advisable	O
to	O
identify	O
the	O
BCR	O
-	I:C1835417
ABL	I:C1835417
transcript	O
type	O
in	O
CML	O
patients	O
at	O
diagnosis	O
,	O
using	O
an	O
empirically	O
verified	O
method	O
,	O
in	O
order	O
to	O
link	O
the	O
detected	O
transcript	O
with	O
the	O
clinical	B:C0455712
findings	I:C0455712
,	O
possible	O
resistance	O
to	O
treatment	O
,	O
and	O
appropriate	O
monitoring	O
methods	I:C1283169
.	O

It	O
might	O
be	O
advisable	O
to	O
identify	O
the	O
BCR	O
-	I:C1835417
ABL	I:C1835417
transcript	O
type	O
in	O
CML	O
patients	O
at	O
diagnosis	O
,	O
using	O
an	O
empirically	O
verified	O
method	O
,	O
in	O
order	O
to	O
link	O
the	O
detected	O
transcript	O
with	O
the	O
clinical	O
findings	I:C0455712
,	O
possible	O
resistance	O
to	O
treatment	B:C0087111
,	O
and	O
appropriate	O
monitoring	O
methods	I:C1283169
.	O

It	O
might	O
be	O
advisable	O
to	O
identify	O
the	O
BCR	O
-	I:C1835417
ABL	I:C1835417
transcript	O
type	O
in	O
CML	O
patients	O
at	O
diagnosis	O
,	O
using	O
an	O
empirically	O
verified	O
method	O
,	O
in	O
order	O
to	O
link	O
the	O
detected	O
transcript	O
with	O
the	O
clinical	O
findings	I:C0455712
,	O
possible	O
resistance	O
to	O
treatment	O
,	O
and	O
appropriate	O
monitoring	B:C1283169
methods	I:C1283169
.	O

